PATHWAY FOR INVESTIGATION OF ADULTS PRESENTING WITH ASCITES. U/S Abdo/pelvis shows ascites without obvious evidence of 1 liver disease

Similar documents
Cancer of Unknown Primary Service

Cancer of Unknown Primary (CUP) Protocol

Cancer of Unknown Primary (CUP)

North of Scotland Cancer Network Clinical Management Guideline for Metastatic Malignancy of Undefined Primary Origin (MUO)

PET IMAGING (POSITRON EMISSION TOMOGRAPY) FACT SHEET

SCOTTISH CANCER REFERRAL GUIDELINES REVIEW 2018

Cancer of Unknown Primary

Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Services. Cancer of Unknown Primary Network Site Specific Group. Clinical Guidelines

Recommendations for cross-sectional imaging in cancer management, Second edition

Sarah Burton. Lead Gynae Oncology Nurse Specialist Cancer Care Cymru

South West Strategic Clinical Network Somerset, Wiltshire, Avon and Gloucestershire (SWAG) Cancer Services

PRIORITIES AND CLINICAL EFFECTIVENESS FORUM

Appendix 4 Urology Care Pathways

Faster Cancer Treatment Indicators: Use cases

South Yorkshire, Bassetlaw and North Derbyshire Cancer Alliance

Urgent referral for suspected cancer in Scotland

National Optimal Lung Cancer Pathway

Guidelines for the Management of Renal Cancer West Midlands Expert Advisory Group for Urological Cancer

Cancer of Unknown Primary

performed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.

1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter.

Lung Cancer - Suspected

North of Scotland Cancer Network Clinical Management Guideline for Mesothelioma

Bladder Cancer Guidelines

NICE guideline on Suspected cancer: recognition and referral (2015) Education package for GPs and Nurse Practitioners Case scenarios

West Midlands Sarcoma Advisory Group

CUP Investigation and Management Guidelines V1 West Midlands SCN Acute Oncology, MSCC and CUP ERG /PJJ/

Cancers of unknown primary : Knowing the unknown. Prof. Ahmed Hossain Professor of Medicine SSMC

Cancer: NICE (symptom based)- what s new November 2016

MSCC CARE PATHWAYS & CASE STUDIES. By Michael Balloch Spine CNS

3.1 Investigations for Patients Presenting with Haematuria Table 1

Unknown Primary Service for patients at Chesterfield Royal Hospital

Louisa Fleure. Advanced Prostate Cancer Clinical Nurse Specialist. Guys and St Thomas NHS Trust

Recognition and Referral of Suspected Cancer - NICE guidance and local initiatives

North of Scotland Cancer Network Clinical Management Guideline for Cancer of the Ovary

Cancer Care Kenya Notes for General Practioners:

Single Suspected Cancer Pathway Definitions pathway start date

Introduction. Please note the toolkit aims to share learning and good practice, but it is, of necessity, brief in nature.

Manchester Cancer. Guidelines for Investigation and Management of Malignancy of Unknown Origin (MUO) / Cancer of Unknown Primary (CUP)

Clinical indications for positron emission tomography

Greater Manchester Commissioning Hub: Cancer Programme. The ACE Programme. Wave 2 Multidisciplinary Diagnostic Centres

Review on Tumour Doubling Time (DT) To review the studies that measuring the actual tumour doubling time for human cancers.

Clinical guideline Published: 27 April 2011 nice.org.uk/guidance/cg122

Navigators Lead the Way

North of Scotland Cancer Network Clinical Management Guideline for Endometrial Cancer

Guideline for the Management of Vulval Cancer

SOUTH THAMES CHILDREN S CANCER NETWORK GROUP. REFERRAL PROTOCOLS AND DIAGNOSIS AND STAGING PROTOCOLS October 2014

Evaluation of Cancer Outcomes Barwon South West Registry

Coversheet for Network Site Specific Group Agreed Documentation

Cancer of Unknown Primary (CUP)

Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer

East Kent Summary Guidance suspected cancer referrals and notes GP reference document May 2018

Manchester Cancer Colorectal Pathway Board: Guidelines for management of colorectal hepatic metastases

COSD & Source of Referral

Joint ASPS & ASAPS Statement on Breast Implant Associated ALCL

Take Home Quiz 1 Please complete the quiz below prior to the session. Use the Multiple Primary and Histology Rules

Gynaecological Oncology Unit Lead

ANZUP SURVEILLANCE RECOMMENDATIONS FOR METASTATIC TESTICULAR CANCER POST-CHEMOTHERAPY

Greater Manchester and Cheshire HPB Unit Guidelines for the Assessment & Management of Hepatobiliary and Pancreatic Disease Chapter 5

Cancer. University of Illinois at Chicago College of Nursing

IMAGING GUIDELINES - COLORECTAL CANCER

How a fully integrated Acute Oncology Service can benefit the busy medical unit

Health Board/Region: All-Wales

Tumour Markers. For these reasons, only a handful of tumour markers are commonly used by most doctors.

MEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site

Greater Manchester Cancer: Guidelines for Investigation and Management of Malignancy of Unknown Origin (MUO) and Cancer of Unknown Primary (CUP)

Transforming Cancer Services for London

GROUP 1: Peripheral tumour with normal hilar and mediastinum on staging CT with no disant metastases. Including: Excluding:

Gynecologic Cancer Surveillance and Survivorship: Informing Practice and Policy

The Urology One-Stop Clinic

Oncology Clinical Program Update. William Sause Medical Director Oncology Clinical Program

Pathway Gynaecology Cancer & Diagnostic Protocol for Inter Trust transfer

pulmonary metastasis 80EE4727C6037E7F69A9981B7E55A238 Pulmonary Metastasis 1 / 6

DEPARTMENT OF ONCOLOGY ELECTIVE

Guideline for the Diagnosis of Breast Cancer

Hereditary Breast and Ovarian Cancer (HBOC) Information for individuals and families

Early Cancer Care FAQ

Referral guidelines for suspected cancer

North of Scotland Cancer Network Clinical Management Guideline for Malignant Melanoma

Cancer Services Position & Recovery Plan June 2015

Ovarian cancer. Quick reference guide. Issue date: April The recognition and initial management of ovarian cancer

Surgical Management of Pulmonary Metastases. Dr AG Jacobs Principal Specialist Dept Cardiothoracic Surgery Steve Biko Academic Hospital

Delivering 62 Day GP Cancer Waits in a Complex Landscape. Hannah Marder Cancer Manager University Hospitals Bristol

LCA Lung Clinical Forum. 21 st October 2014

Oncology 101. Cancer Basics

Triage of Ovarian Masses. Andreas Obermair Brisbane

Clinical Biochemistry Department City Hospital

Louisa Fleure. Advanced Prostate Cancer Clinical Nurse Specialist. Guys and St Thomas NHS Trust

Liver and Pancreatic Case discussion

Screening tests. When you need them and when you don t

Lung Cancer Case Study

NICE BULLETIN Diagnosis & treatment of prostate cancer

NICE Quality Standards and COF

Colorectal Cancer Care

Alison Douglass Gillian Lieberman, MD. November. Colon Cancer. Alison Douglass, Harvard Medical School Year III Gillian Lieberman, MD

Specialist Referral Service Willows Information Sheets. Cancer in cats and dogs: Assessment of the patient

Upper GI Malignancies Imaging Guidelines for the Management of Gastric, Oesophageal & Pancreatic Cancers 2012

Rapid referral toolkit

General Surgery Curriculum Royal Australasian College of Surgeons, General Surgeons Australia & New Zealand Association of General Surgeons

West Midlands Sarcoma Advisory Group

Transcription:

PATHWAY FOR INVESTIGATION OF ADULTS PRESENTING WITH ASCITES U/S Abdo/pelvis shows ascites without obvious evidence of 1 liver disease Refer back to original requester with this paperwork and review previous imaging Comprehensive history and examination and appropriate blood tests (Appendix 1) Including performance status (Appendix 2) (If status 3 or 4 consider direct oncology referral or palliative care for symptom control) Primary site suspected Refer to appropriate Rapid Access clinic Primary site unknown (GP to request) CT chest/abdomen/pelvis FEMALES MALES No primary identified No primary identified Refer Gynae MDT Refer Colo-Rectal MDT Primary identified Refer to appropriate MDT 1 MUO/CUP Presenting symptoms Pathways 2017_DP

Appendix 1 COMPREHENSIVE HISTORY AND EXAMINATION OF PATIENT PRESENTING WITH ASCITES, INCLUDING: Family history of ovarian or breast cancer Change in bowel habit Rectal examination abnormal Breast examination abnormal Symptoms/signs of lung cancer (including haemoptysis) Dyspeptic symptoms or epigastric pain suggestive of upper GI cancer Haematuria Testicular examination abnormal Thyroid examination abnormal Enlarged lymph nodes If the answer to any of the above is yes the patient should be referred to the appropriate Multidisciplinary Team using a 2-week wait form. Blood tests prior to referral FBC Full biochemistry CEA CA125 (women only) Appendix 2 0 Normal activity 1 Strenuous activity restricted, can do light work 2 Up and about > 50% of waking hours. Capable of self care 3 Confined to bed > 50% of waking hours. Limited self care 4 Confined to bed or chair. No self care. Completely disabled 2 MUO/CUP Presenting symptoms Pathways 2017_DP

PATHWAY FOR INVESTIGATION OF ADULTS PRESENTING WITH RADIOLOGICAL SUSPICION OF A BONE TUMOUR X-ray (or other imaging), shows a suspicious bony lesion Refer back to original requester with letter and this paperwork and review previous imaging Comprehensive history and examination (Appendix 1) Including performance status (Appendix 2) (3 or 4 consider direct oncology referral or palliative care for symptom control) Appropriate blood tests (Appendix 1) Primary site suspected Refer to appropriate Rapid Access clinic Primary site unknown (GP to request) CT chest/abdomen/pelvis Lung metastases on CT Liver metastases on CT Refer Chest MDT Refer Colo-Rectal MDT No primary site identified, no lung or liver mets and no additional bone secondaries (GP to request) Bone scan Multiple lesions Solitary lesion Female Male Refer Mr Sjolin Mr Nicolai or Breast MDT Mr Wood or Urology MDT 3 MUO/CUP Presenting symptoms Pathways 2017_DP

Appendix 1 COMPREHENSIVE HISTORY AND EXAMINATION OF PATIENT PRESENTING WITH SUSPICION OF A BONE TUMOUR, INCLUDING: Change in bowel habit Rectal examination abnormal Breast examination abnormal Symptoms/signs of lung cancer (including haemoptysis) Dyspeptic symptoms or epigastric pain suggestive of upper GI cancer Haematuria Testicular examination abnormal Thyroid examination abnormal Enlarged lymph nodes If the answer to any of the above is yes the patient should be referred to the appropriate Multidisciplinary Team using a 2-week wait form. Blood tests prior to referral FBC EC LFTs Calcium PSA in men (if > 10 refer to Urology Team) Immunoglobulins Appendix 2 0 Normal activity 1 Strenuous activity restricted, can do light work 2 Up and about > 50% of waking hours. Capable of self care 3 Confined to bed > 50% of waking hours. Limited self care 4 Confined to bed or chair. No self care. Completely disabled 4 MUO/CUP Presenting symptoms Pathways 2017_DP

INVESTIGATION PATHWAY FOR PATIENTS PRESENTING WITH BRAIN SECONDARIES, UNKNOWN PRIMARY SITE CT shows probable brain metastases Refer back to original requester with this paperwork and review previous imaging Assess performance status 3 or 4 Refer to GP & Consider palliative care/ counselling (appendix 1) (appendix 2) 0, 1 or 2 Exceptional circumstances Abnormal Careful history and examination Specialist referral and further investigations as appropriate via Rapid Access route Normal No pointers to primary site CT chest/abdomen/pelvis Primary site identified No primary site identified Discuss at appropriate MDT +/ tissue biopsy Refer to oncologist 5 MUO/CUP Presenting symptoms Pathways 2017_DP

INVESTIGATION PATHWAY FOR PATIENTS PRESENTING WITH HEPATIC SECONDARIES, UNKNOWN PRIMARY Ultrasound shows hepatic secondaries CXR whilst patient in dept Normal CXR or lung secondaries Probable lung primary Refer back to original requester Refer chest physicians CACXR 3 or 4 1. Confirm performance status [Refer back to GP]; consider palliative care if symptoms indicate need or consider counselling 0, 1, 2 Exceptional circumstances Abnormal 2. And retake history and examination Refer via Rapid Access to appropriate Clinical Team (Appendix 3) Normal No pointers to primary site GP to request CT (and confirm normal U&E, FBC) CT confirms colorectal Ca CABE CT shows no evidence of colorectal Ca 6 MUO/CUP Presenting symptoms Pathways 2017_DP

Review colorectal MDT Review C-R MDT Image guided liver Bx under Enema/ care of colorectal surgeons Colonoscopy) (Ba Histology directs oncologist/mdt referral 7 MUO/CUP Presenting symptoms Pathways 2017_DP

INVESTIGATION PATHWAY FOR PATIENTS PRESENTING WITH LUNG SECONDARIES, UNKNOWN PRIMARY SITE CXR or CT shows probable lung metastases Refer back to original requester with this paperwork and review previous imaging Assess performance status 3 or 4 Refer to GP & consider palliative care/counselling circumstances Exceptional (appendix 1) 0, 1 or 2 Abnormal Careful history and examination (appendix 2) Specialist referral and further investigations as appropriate Normal No pointers to primary site Review at Lung MDT CT scan thorax/abdomen/pelvis Tumour markers Histological sampling as appropriate 8 MUO/CUP Presenting symptoms Pathways 2017_DP

Appendix 1 COMPREHENSIVE HISTORY AND EXAMINATION OF PATIENT PRESENTING WITH PULMONARY METASTASES, INCLUDING : Head and neck examination for obvious primary including thyroid or lymphadenopathy. Haematuria/palpable renal mass Symptoms/signs of primary lung carcinoma (including haemoptysis) Skin inspection for melanoma or other skin cancer Signs/symptoms of bone/soft tissue sarcoma Breast examination Testes Signs and symptoms of other primary site, eg : Colorectal Upper GI Prostate Ovary Pancreas Will usually spread to other sites, especially liver and peritoneum before lung If the answer to any of the above is yes the patient should be referred to the appropriate team using a two-week wait form. Appendix 2 0 Normal activity 1 Strenuous activity restricted, can do light work 2 Up and about > 50% of waking hours. Capable of self care 3 Confined to bed > 50% of waking hours. Limited self care 4 Confined to bed or chair. No self care. Completely disabled 9 MUO/CUP Presenting symptoms Pathways 2017_DP

INVESTIGATION PATHWAY FOR PATIENTS PRESENTING WITH A SOLITARY BRAIN TUMOUR? SOLITARY SECONDARY CT shows solitary brain tumour Refer back to original requester with this paperwork and review previous imaging Assess performance status 3 or 4 Refer to GP & consider palliative care/ counselling (appendix 1) 0, 1 or 2 Careful history and examination (appendix 2) Exceptional circumstances Abnormal Specialist referral and further investigations as appropriate via Rapid Access route Normal No pointers to possible primary site Probable primary identified CT chest/abdomen/pelvis MRI brain Normal Refer Neuro-Oncology MDT or d/w Addenbrooke s CNS 10 MUO/CUP Presenting symptoms Pathways 2017_DP

PATHWAY FOR INVESTIGATION OF ADULTS PRESENTING WITH A SYMPTOMATIC MALIGNANT PLEURAL EFFUSION Pathological confirmation of malignant pleural effusion Comprehensive history and examination and appropriate blood tests (Appendix 1) Including performance status (Appendix 2) (If status 3 or 4 consider direct oncology referral or palliative care for symptom control) CXR suggestive of lung primary Refer to chest MDT Other primary site suspected (Clinically or on immunohistochemistry) Refer to appropriate Rapid Access clinic /team Primary site unknown CT chest/abdomen/pelvis FEMALES MALES No primary identified No primary identified Refer Breast MDT Refer Chest MDT Primary identified Refer to appropriate MDT 11 MUO/CUP Presenting symptoms Pathways 2017_DP

Appendix 1 COMPREHENSIVE HISTORY AND EXAMINATION OF PATIENT PRESENTING WITH PLEURAL EFFUSUION, INCLUDING: Symptoms/signs of primary lung carcinoma (including haemoptysis) Asbestos exposure (Mesothelioma/lung cancer) Dyspeptic symptoms or epigastric pain suggestive of upper GI cancer Skin inspection for melanoma or other skin cancer Breast examination Enlarged lymph nodes Testes Signs and symptoms of other primary site, eg: Lower GI Prostate Ovary Will usually spread to other sites, especially liver and peritoneum before pleura If the answer to any of the above is yes the patient should be referred to the appropriate team using a two-week wait form. Blood tests prior to referral: FBC Full biochemistry AFP & βhcg (men only) Appendix 2 0 Normal activity 1 Strenuous activity restricted, can do light work 2 Up and about > 50% of waking hours. Capable of self care 3 Confined to bed > 50% of waking hours. Limited self care 4 Confined to bed or chair. No self care. Completely disabled 12 MUO/CUP Presenting symptoms Pathways 2017_DP

PATHWAY FOR INVESTIGATION OF ADULTS PRESENTING WITH A SYMPTOMATIC MALIGNANT PERICARDIAL EFFUSION Pericardial effusion confirmed on echocardiogram (effusion managed appropriately by cardiology) Comprehensive history and examination and appropriate blood tests (Appendix 1) Including performance status (Appendix 2) (If status 3 or 4 consider direct oncology referral or palliative care for symptom control) CXR suggestive of lung primary Refer to chest MDT Other primary site suspected Refer to appropriate Rapid Access clinic /team Primary site unknown CT chest/abdomen/pelvis FEMALES MALES No primary identified No primary identified Refer Breast MDT Refer Chest MDT Primary identified Refer to appropriate MDT 13 MUO/CUP Presenting symptoms Pathways 2017_DP

Appendix 1 COMPREHENSIVE HISTORY AND EXAMINATION OF PATIENT PRESENTING WITH PERICARDIAL EFFUSUION, INCLUDING: Symptoms/signs of primary lung carcinoma (including haemoptysis) Asbestos exposure (Mesothelioma/lung cancer) Dyspeptic symptoms or epigastric pain suggestive of upper GI cancer Skin inspection for melanoma or other skin cancer Breast examination Enlarged lymph nodes Testes Signs and symptoms of other primary site, eg : Colorectal Prostate Ovary Will usually spread to other sites, especially liver and peritoneum before pericardium If the answer to any of the above is yes the patient should be referred to the appropriate team using a two-week wait form. Blood tests prior to referral: FBC Full biochemistry AFP & βhcg (men only) Appendix 2 0 Normal activity 1 Strenuous activity restricted, can do light work 2 Up and about > 50% of waking hours. Capable of self care 3 Confined to bed > 50% of waking hours. Limited self care 4 Confined to bed or chair. No self care. Completely disabled 14 MUO/CUP Presenting symptoms Pathways 2017_DP